Case Report: Gastric Carcinoma Diagnosed at the Second Trimester of Pregnancy

We report a rare case of gastric cancer in pregnancy. A 26-year-old woman presented at the 20th week of pregnancy complaining of nausea and vomiting. Although the patient considered the condition to be related with pregnancy and underestimated its importance, her complaints persisted over the following weeks and she was hospitalized for investigation. The diagnostic workup revealed a metastatic gastric cancer. Gastric cancer is very rare in pregnancy, and therefore it may be left out of differential diagnosis by physicians. Diagnosis may be further delayed because of overlapping symptoms occurring during normal pregnancy (nausea, vomiting, and fatigue). All these factors may contribute to a very high mortality of this malignancy during pregnancy

Unusual uterine metastasis of invasive ductal carcinoma: A case report

Metastatic carcinoma of the uterus usually originates from other genital sites. Extragenital metastases such as breast are rare. A woman aged 34 years with a history of breast cancer was referred to the gynecology outpatient clinic for routine follow-up. Diagnostic tests and gynecologic examination revealed a uterine mass, which was removed with laparotomy. The pathologic investigation revealed metastasis of invasive lobular breast cancer. Chemotherapy was given and the patient has been under follow-up for 3 years with normal imaging on computerized tomographic examination and positron-emission tomography-computerized tomographic. It should be kept in mind that patients with breast cancer who have received tamoxifen may develop primary endometrial cancers, and may also demonstrate uterine metastases. With successful treatment these patients can obtain dis-ease-free survival

Effects of amniotic and maternal CD-146, TGF-beta 1, IL-12, IL-18 and Inf-gamma, on adverse pregnancy outcome

Objective: Our aim was to determine the effects of maternal serum and amniotic fluid levels of cluster of differentiation 146 (CD-146), transforming growth factor (TGF)-beta 1, interleukin (IL)-12, IL-18, and interferon (IFN)-gamma on intrauterine growth restriction and preterm labor. Methods: In this retrospective cohort study, we included pregnant women who underwent amniocentesis at Istanbul University Cerrahpasa Medical School. Women were followed up to labor. The study group comprised 23 women with adverse pregnancy outcomes (intrauterine growth restriction and preterm labor), and the control group comprised 105 women with normal pregnancy outcome. Results: The study group was further divided into two subgroups of preterm labor and intrauterine growth restriction. No significant differences were found for IL-12, IFN-gamma, TGF-beta 1, or CD-146 levels in either plasma or amniotic fluid between the study and control groups. Serum IL-18 levels were similar, but the amniotic fluid level of IL-18 was significantly higher in the intrauterine growth restriction subgroup than that in the preterm labor subgroup and that in the control group (p < 0.01). Conclusions: Increased IL-18 level in amniotic fluid may be a predictor for intrauterine growth restriction. IL-12, IFN-gamma, TGF-beta 1, and CD-146 were not related to adverse pregnancy outcome

Pregnancy outcomes in women with heart disease

To evaluate the maternal and fetal outcome of pregnancies complicated by cardiac disease in a developing country

Oocyte pick up day mucus removal: Does it have a positive effect on pregnancy rates?

Aim: Mucus removal that would be done on the day of embryo transfer could be done on Oocyte pick up(OPU) day, and this practice might be related with better pregnancy rates since it is unlikely to cause uterine contractions during the embryo transfer. We compared the effects of mucus removal done on OPU day, transfer day or no removal at all on success rates of the treatment in three groups. Material and Method: We designed a prospective match control study. There were 131 cycles in which mucus removal was done on either OPU day or embryo transfer day (64 and 67 cycles respectively) and in 411 cycles mucus removal was not done, and these patients constituted the control group. Results: After mucus removal on OPU day, mucus removal on embryo transfer day and no mucus removal done at all, pregnancy rates were calculated as 40,6%, 29,9%, and 23,1% respectively and the difference among the groups was statistically significant (p=0,009). Discussion: Mucus removal on OPU day or on embryo transfer day improves pregnancy rates. It can be included in the routine practice, since it may potentially minimize cervical trauma and uterine contractions and thus improve success in IVF/ICSI treatments

Recurrent Implantation Failure Is More Frequently Seen in Female Patients with Poor Prognosis

Background: This study evaluated the characteristics and results of patients who suffer from recurrent implantation failure (RIF)

The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia

Aim: To investigate both maternal and umbilical cord adropin levels in patients with preeclampsia and the possible relations with its severity and perinatal outcomes

Serum Levels of Epidermal Growth Factor, Transforming Growth Factor, and c-erbB2 in Ovarian Cancer

Objective: This study aimed to investigate serum levels of epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha), and c-erbB2 in patients with ovarian cancer

The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia

Aim: To investigate both maternal and umbilical cord adropin levels in patients with preeclampsia and the possible relations with its severity and perinatal outcomes. Materials and methods: In this study, a total of 38 preeclamptic and 40 age- matched healthy pregnant women between January and June 2016 were included. Serum and cord adropin levels were measured using an enzymelinked immunosorbent assay (ELISA). Results: The maternal and umbilical cord adropin levels were significantly lower in the preeclamptic group compared to controls [71.19 +/- 22.21 vs. 100.76 +/- 27.02 ng/L and 92.39 (59.77:129.89) vs. 106.20 (74.42: 208.02) ng/L, P < 0.001, respectively]. While maternal adropin levels were significantly lower in the severe preeclampsia group as compared to the mild preeclamptic group [66.45 (21.49:98.02) vs. 76.17 (58.06:109.58), P = 0.007], umbilical cord adropin levels did not differ between each group [91.32 (59.77:113.34) vs. 92.87 (63.12:129.89), P = 0.750]. Maternal adropin level was negatively correlated with systolic and diastolic blood pressures (r = - 0.60, P < 0.001 and r = - 0.58, P < 0.001, respectively) and positively correlated with platelet count (r = 0.27, P = 0.016). Moreover, umbilical cord adropin levels were weakly correlated with gestational age at delivery (r = 0.28, P = 0.012) and birth weight (r = 0.28, P = 0.014). Conclusion: The present study is the first to demonstrate a significant association between maternal and umbilical adropin levels and the presence and severity of preeclampsia. Adropin might be a useful parameter for predicting the presence and severity of preeclampsia